Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06099730 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

A NA study of Atrial Fibrillation, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
360
Enrollment target
7
Study locations

NCT06099730 is a NA study of Atrial Fibrillation that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 360 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06099730, a NA study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
360 participants
Enrollment target
7
Study locations

Study Summary

The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation with the VARIPULSE™ catheter and the TRUPULSE™ generator.

Conditions Studied

Atrial Fibrillation

Interventions

  • DEVICE Pulsed Field Ablation (PFA)

Study Locations (7)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

New York

  • Mount Sinai Hospital - New York
  • Montefiore Medical Center - New York

Arkansas

  • St. Bernard's Heart and Vascular Center - Jonesboro

Ohio

  • Cleveland Clinic - Cleveland

Texas

  • Texas Cardiac Arrhythmia Institute/Research Foundation - Austin

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2023-12-14
Est. Completion 2026-11
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06099730

The ClinicalTrials.gov registry entry for NCT06099730 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Pulsed Field Ablation (PFA) is the first listed.

NCT06099730 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, New York, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06099730 about?

NCT06099730 is a clinical study titled "Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF". The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation w...

What is the current status of trial NCT06099730?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 360 participants. The study started on 2023-12-14. Estimated completion is 2026-11.

What conditions does trial NCT06099730 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT06099730?

The interventions under investigation include: Pulsed Field Ablation (PFA) (DEVICE).

Who is sponsoring clinical trial NCT06099730?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06099730 being conducted?

This trial has 7 study locations across Arkansas, Massachusetts, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.